Claims for Patent: 5,635,523

Summary for Patent: 5,635,523

Title:	Retroviral protease inhibiting compounds
Abstract:	A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s):	Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	08/417,879
Patent Claims:	1. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a reverse transcriptase inhibitor. 2. The method of claim 1 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), BCH-189, 5-halo-3'-thia-dideoxycytidine, PMEA, zidovudine (AZT). 3. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of zidovudine. 4. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of dideoxycytidine. 5. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of dideoxyinosine. 6. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl-amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of D4T. 7. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of a 5-halo-3'-thia-dideoxycytidine. 8. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of BCH-189. 9. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of zidovudine and a therapeutically effective amount of one or more other reverse transcriptase inhibitors selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, DDA, D4C, D4T and DP-AZT. 10. A method for inhibiting an HIV infection comprising administering to a human in need thereof a therapeutically effective amount of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-dipheny l-3-hydroxyhexane or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of zidovudine and a therapeutically effective amount of BCH-189.